Bli medlem
Bli medlem

Du är här


WntResearch: WntResearch announces that the Phase 1b study with Foxy-5 is approved

WntResearch today announces that the Danish regulatory authorities and
the ethics committee have approved the protocol for the Phase 1b
study with Foxy-5. Thus, the study will start immediately.

With the Danish regulatory authorities and the ethics committee having
approved the protocol for the previously announced Phase 1b study
with Foxy-5, two Danish research centres (Rigshospitalet in
Copenhagen and Herlev University Hospital), will now begin
recruitment of patients for the study.

Furthermore, WntResearch can also announce that Northern Centre for
Cancer Care (NCCC) at Freeman Hospital, Newcastle, UK has been
included as a research center in the study. As previously announced
R&D Centre at Skåne University Hospital in Lund, Sweden is also
included in the study. Hence, when final approvals are achieved a
total of four sites will be part of the study.

CEO Henrik Lawaetz comments: "We are very pleased that the Phase 1b
study now will be initiated. The study will be followed by a
randomized phase 2 study in cancer patients with no or minimal
metastatic disease, but a high risk of disease recurrence. We are
also pleased with the inclusion of NCCC in Newcastle in the study,
and hope this will increase the patient inclusion rate."

CMO Nils Brünner comments: "We expect that the phase 1b study will
give us information that we will use to optimize the conditions for
the upcoming Phase 2 study. It will be particularly interesting to
analyze the new biomarkers that will be used to monitor the effects
of Foxy-5."

For additional information please contact:
Henrik Lawaetz, CEO
Telephone: + 45 20135298

About WntResearch
WntResearch has entered the clinical development phase with the
company's first drug candidate, Foxy-5, which in animal models has
been shown to dramatically inhibit the spreading of tumors
(metastasis). The company goal is to commercialize new drugs against
tumor metastasis. WntResearch is based on research from Professor
Tommy Andersson and his research group at Lund University. Their
research is aimed at developing innovations based on the protein
Wnt-5a and its role in cancer. In addition to Foxy-5, which is in
phase 1 clinical development, the company has a preclinical
development program - Box-5. WntResearch AB is a public company
listed on AktieTorget.

For more information see


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.